Shares of St. Jude Medical fell after the FDA released a plant inspection report that found problems in the company’s testing and oversight of an electrical wire, or lead, that connects an implanted defibrillator to a patient’s heart. The FDA report raises the prospect of potential agency action. St. Jude executives have repeatedly insisted the lead is safe.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help